T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Mp34-11 neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology
Malte W. Vetterlein,Stephanie A. Mullane,Thomas Seisen,Richard Lander,Björn Löppenberg,Toni K. Choueiri,Joaquim Bellmunt,Mani Menon,Adam S. Kibel,Quoc-Dien Trinh,Mark A. Preston +10 more
TL;DR: A scoring system for RC that can provide structured feedback for surgical quality assessment, training and feedback is developed and validated.
Journal ArticleDOI
702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
Sumanta K. Pal,C-K. Tsao,Cristina Suarez,Wm. Kevin Kelly,Luigi Pagliaro,Ulka N. Vaishampayan,Yohann Loriot,S. Srinivas,Bradley Alexander McGregor,Ashok Panneerselvam,Dominic Curran,Toni K. Choueiri,Neeraj Agarwal +12 more
Journal ArticleDOI
Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).
Toni K. Choueiri,Brian I. Rini,James Larkin,Georg A. Bjarnason,Gwenaelle Gravis,Howard Gurney,Jae-Lyun Lee,Daniel Keizman,John B. A. G. Haanen,Yoshihiko Tomita,Hirotsugu Uemura,Laurence Albiges,Manuela Schmidinger,Michael B. Atkins,Mariangela Mariani,Michael Shnaidman,Alessandra di Pietro,Robert J. Motzer +17 more
TL;DR: JAVELIN Renal 101 is a randomized, multicenter, phase 3 study comparing avelumab + axit inib vs sunitinib in pts with treatment-naive aRCC, and the primary objective is to demonstrate superiority of avelUMab +Axitin ib.
Journal ArticleDOI
CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.
Sumanta K. Pal,Laurence Albiges,Cristina Suarez Rodriguez,Bo Liu,Jennifer Doss,Sudha Khurana,Christian Scheffold,Martin H. Voss,Toni K. Choueiri +8 more
TL;DR: Combining anti-angiogenic drugs with immune checkpoint inhibitors (ICI) after progression on ICIs presents a promising therapeutic approach in renal cell carcinoma (RCC).
Journal ArticleDOI
Use of Surveillance Imaging Following Treatment of Small Renal Masses
Keith J. Kowalczyk,Andrew Harbin,Toni K. Choueiri,Nathanael D. Hevelone,Stuart R. Lipsitz,Quoc-Dien Trinh,Quoc-Dien Trinh,Ya Chen Tina Shih,Jim C. Hu +8 more
TL;DR: Although possibly associated with lower morbidity, thermal ablation is associated with significantly greater use of imaging compared to other small renal mass treatments, which may increase costs and radiation exposure.